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Neoadjuvant Therapy Offers Longer Survival than Upfront Surgery 
for Poorly Differentiated and Higher Stage Pancreatic Cancer   
Background: Neoadjuvant therapy for pancreatic cancer remains controversial. Our aim was to 
assess differences in survival, disease recurrence and histopathological tumour characteristics 
between patients treated with neoadjuvant therapy followed by subsequent surgery and patients 
undergoing upfront surgery. 
Material and Methods: Out of 399 consecutive pancreatic ductal adenocarcinoma (PDAC) 
patients operated at Helsinki University Hospital in 2000 to 2015, 75 borderline resectable 
patients were treated with neoadjuvant therapy. Resectable propensity scored patients (n=150) 
underwent upfront surgery. Neoadjuvant therapy consisted of folfirinox, single gemcitabine or 
combined with cisplatin, nab-paclitaxel or capecitabine with or without radiation. Survival was 
calculated with Kaplan-Meier and compared with the Breslow test. Survival was determined 
from the start of treatment, being the first day of treatment for patients treated with neoadjuvant 
therapy and the date of surgery for others. 
Results: Between 2000 and 2015 median disease-specific survival (DSS) [34 (95% CI 29-39) 
vs. 26 (20-32) months, p=0.016] and disease-free survival (DFS) [22 (17-27) vs. 13 (9-17) 
months, p=0.001] were longer in patients treated with neoadjuvant therapy than in those 
undergoing upfront surgery. Survival differences were not significant in the 2000s but were, in 
turn, among patients treated in the 2010s with better survival for patients treated with 
neoadjuvant therapy [DSS 35 (25-44) vs. 26 (20-31) months, p=0.008 and DFS 25 (13-36) vs. 
13 (6-21) months, p=0.001]. Neoadjuvant therapy offered longer survival especially for patients 
with poorly differentiated G3 tumours HAD LONGER SURVIVAL [DSS 30 (17-42) vs. 11 (8-
15) months, p=0.004 and DFS 21 (11-31) vs. 7 (5-8) months, p=0.001] and higher stage IIB-III 
[DSS 34 (29-40) vs. 20 (14-26) months, p=0.006 and DFS 21 (12-29) vs. 10 (7-13) months, 
p=0.001].  
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Conclusions: Neoadjuvant therapy offers PDAC patients longer DSS and DFS than upfront 
surgery. Neoadjuvant therapy benefits especially borderline resectable patients with higher stage 
and poorly differentiated tumours.  
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Introduction 
 
Pancreatic cancer is one of the most fatal cancers with an extremely poor overall five-
year survival rate ranging from 5% to 8% [1,2]. Effective treatment regimens are 
lacking and the fatality of the disease is due to aggressiveness, advanced or metastatic 
disease at diagnosis and high recurrence rate [3]. Pancreatic ductal adenocarcinoma 
(PDAC) represents >90% off all exocrine pancreatic malignancies and holds the worst 
survival [4]. Margin negative surgery combined with oncological treatment is the only 
curative-intent treatment option with substantially higher survival rate, however, only 
15% to 20% of the patients appear operable [5,6]. Despite advantages in research over 
the past decades, five-year overall survival rate has not improved drastically [1,3,7], and 
it has been predicted that PDAC continues to cause even more cancer-related deaths by 
2030 due to lack of effective treatments and early detection [8]. 
Recently, neoadjuvant therapy in the management of PDAC has been a 
target of avid research. In the best-case scenario neoadjuvant therapy can downstage 
locally advanced tumours and increase the likelihood of R0 resection in borderline 
resectable cases [9,10]. Neoadjuvant approach to borderline resectable patients can also 
identify patients who are unlikely to benefit from surgery due to advanced disease 
[9,11]. However, administration of neoadjuvant therapy for resectable PDAC is still 
controversial in terms of patient selection [12,13]. With high recurrence rates, it has 
been postulated that PDAC is most likely a systemic disease at diagnosis [14] and 
hence, should be treated with neoadjuvant therapy. Furthermore, research shows that 
patients more likely complete neoadjuvant than adjuvant therapy indicating that 
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systemic therapy before surgery increases the likelihood of multimodal treatment 
[15,16]. However, it has been debated if administration of neoadjuvant therapy may 
endanger the possibility of surgery in progressive disease [17].  It is unclear why some 
patients with PDAC survive longer than others with the same kind of treatment. 
Recently, PDAC research has focused on personalised medicine and thus, more reliable 
and adaptable patient-specific prognostic factors and treatment options are needed.  
The aim of this study was to compare disease-specific (DSS) and disease-
free survival (DFS) and histopathological tumour characteristics in patients treated with 
neoadjuvant therapy and patients undergoing upfront surgery. We also explored 
possible sub-populations who would preferably benefit from neoadjuvant therapy over 
upfront surgery.  
 
Material and Methods 
 
Patients 
We conducted a search for PDAC patients from the Helsinki University Hospital 
database and found in total 399 consecutive PDAC patients operated between January 
2000 and December 2015 of which 75 borderline resectable patients were treated with 
neoadjuvant therapy and subsequent surgery. Propensity scored patients with matched 
age, sex and time of surgery (n=150) underwent upfront surgery. Patient characteristics 
and survival data were collected from patient records and the Finnish Population 
Registry. Cause of death was obtained from Statistics Finland. The study was approved 
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by the Surgical Ethics Committee and the National Supervisory Authority of Welfare 
and Health. Helsinki University Hospital follows a standardised pancreatic resection 
procedure [6]. Staging of patients was determined according to the 7th edition of 
Pancreas cancer staging of American Joint Committee on Cancer (AJCC).  
Patient characteristics are presented in Table 1 [Table 1 near here]. 
Median follow-up time was 2.1 years. Stage IV patients (n=2) were excluded from 
survival analyses. Three T0 patients (4%) were recorded in the neoadjuvant group. Prior 
to neoadjuvant therapy these patients had histologically confirmed PDAC. One of these 
patients had pathologically confirmed regional lymph node PDAC metastasis, resulting 
in two stage 0 complete responses. These two patients with stage 0 disease have lived 
for 4.8 and 4.2 years with no disease progression observed to date.  
No difference in the administration of postoperative treatment was 
observed between patient groups. Out of the 48 (65%) patients treated with neoadjuvant 
therapy who were administered postoperative adjuvant therapy, 35 (73%) completed the 
given regimen. For those undergoing upfront surgery, 102 (68%) were administered 
adjuvant therapy and 66 (65%) were able to complete it. Survival analyses according to 
adjuvant therapy were calculated for all patients receiving adjuvant therapy, including 
those who were not administered the full adjuvant regimen. No significant differences 
in postoperative complications, including postoperative mortality, were recorded.  
 
Neoadjuvant Therapy and Resectability 
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Neoadjuvant therapy was administered to borderline resectable patients only with the 
exception of one resectable patient taking part in a clinical trial. There were nine 
patients whose scans were not available to determine preoperative staging. Borderline 
resectable was defined as contact with the superior mesenteric vein or the portal vein 
with no distant metastases. Neoadjuvant therapy regimens consisted of folfirinox, single 
gemcitabine or combined with cisplatin, cabecitabin or nab-paclitaxel. Additional 
radiotherapy was administered to 29 (39%) patients. Radiotherapy alone was 
administered to one patient due to comorbidity. Tumour diameter in the axial plane was 
measured before and after neoadjuvant therapy on contrast-enhanced CT scans or, when 
unavailable, on MRI scans. The surgical tissue specimen were reviewed to confirm 
PDAC diagnosis. 
 
Statistics 
Fisher’s exact test and linear-by-linear association were used for categorical variables. 
Mann-Whitney U-test was used for continuous variables and survival was estimated 
with the Kaplan-Meier method. Survival was compared with the Breslow test. Breslow 
denotes the early survival differences which in pancreatic cancer are more meaningful 
due to the dismal five-year survival rate. The main Kaplan-Meier analyses were, in 
addition, carried out with a landmark analysis; the landmark time was chosen as the 
median duration of neoadjuvant therapy. Multivariate analyses were carried out by 
using the Cox proportional hazards method. Tumour grade, stage, LNR, neoadjuvant 
therapy and adjuvant therapy were included in the multivariate model. The assumption 
of constant proportional hazard rate over time was tested by adding a time dependent 
 8 
variable for each variable at a time. All variables met the assumption. Multivariate 
analyses were calculated with a time-dependent factor taking into account the time of 
surgery from the beginning of treatment to cover guarantee-time bias. Survival was 
calculated from the start of treatment, which was the first day of treatment for patients 
treated with neoadjuvant therapy and date of surgery for others, to death due to 
pancreatic cancer in DSS and disease progression first recorded in DFS. All statistical 
analyses were calculated with SPSS (v22, IBM, New York, NY, USA). A p-value <0.05 
was considered significant and two-tailed tests were used. 
 
Results 
 
Between 2000 and 2015 (n=223) both median DSS and DFS were significantly longer 
in patients treated with neoadjuvant therapy than in patients undergoing upfront surgery 
[Table 2][Table 2 near here]. Patients treated in 2000-2009 (n=91) had no difference in 
DFS or DSS between compared groups, whereas, patients treated in 2010-2015 (n=132) 
showed a significant difference in both DSS and DFS between groups; patients treated 
with neoadjuvant therapy had both longer median DSS [Figure 1A] and DFS [Figure 
1B] than patients undergoing upfront surgery [Table 2][Figures 1A and 1B near here].  
Comparing patients treated with neoadjuvant therapy median DFS was 
longer in patients treated in 2010-2015 than in patients treated in 2000-2009, whereas, 
increase in DSS did not reach statistical difference. However, in patients undergoing 
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upfront surgery, no progress in DFS or DSS was observed between patients treated in 
2000-2009 and 2010-2015[Supplement 1].  
DSS and DFS were first evaluated according to tumour grade, stage and 
resection margins separately in patients treated with neoadjuvant therapy and those 
undergoing upfront surgery. DSS and DFS were additionally compared between 
patients treated with neoadjuvant therapy and patients undergoing upfront surgery 
according to these prognostic factors [Table 3][Table 3 near here]. A significant 
difference in favour of neoadjuvant therapy was noted in patients with poorly 
differentiated grade 3 tumour in both median DSS (30 vs. 11 months, p=0.004) [Figure 
2A] and DFS (21 vs. 7 months, p=0.001) [Figure 2B][Figures 2A and 2B near here]. 
When dividing patients into groups according to stage and lymph node status, 0-IIA and 
IIB-III, there were no survival differences between groups. However, median DSS (34 
vs. 20 months, p=0.006) [Figure 3A] and DFS (21 vs. 10 months, p=0.001)[Figure 3B] 
were recorded to be longer in patients with higher stage (IIB-III) treated with 
neoadjuvant therapy than upfront surgery [Figures 3A and 3B near here].  
In the multivariate model including tumour grade, stage, LNR, 
neoadjuvant and adjuvant therapy, there were significant interactions between tumour 
grade and neoadjuvant therapy. Therefore, the model was split by tumour grade. After 
adjusting for other factors, neoadjuvant therapy presented with a protective effect on 
DSS and DFS in grade 3 patients (HR 0.37; 95% CI 0.17-0.84, p=0.018 and 0.40; 95% 
CI 0.17-0.92, p=0.030, respectively) [Supplement 2 and 3].  
Grouping patients according to preoperative and postoperative treatment 
revealed that patients receiving perioperative treatment had both longest DSS and DFS 
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compared to those treated with neoadjuvant therapy and surgery and those treated with 
upfront surgery with or without adjuvant therapy. [Supplement 4].  
Median time between the start of neoadjuvant therapy and surgery was 4 
months (range 2-12 months, IQR 3-6 months). When comparing neoadjuvant regimens 
in 2000-2009 and 2010-2015, new agents such as folfirinox and nab-paclitaxel had been 
administered. Also, different agents were combined more often in the 2010s than in the 
2000s [Supplement 6]. All adjuvant therapy regimens are listed in [Supplement 7].  
 
Discussion 
 
Whereas improvements in surgical techniques and perioperative care have decreased 
mortality and morbidity after surgery for pancreatic cancer, the overall survival of 
pancreatic cancer has not improved much during the past decades [1,18]. This study 
demonstrates that there has been some improvement in the survival of pancreatic 
cancer. Survival for borderline resectable patients treated with neoadjuvant therapy has 
improved during the past 15 years. These results offer hope for pancreatic cancer 
patients since neoadjuvant therapy gives patients with advanced disease a chance at 
resection and thus, the possibility of longer survival.  
Over the studied time period, a comparison between patients treated with 
neoadjuvant therapy and those undergoing upfront surgery showed that both DSS and 
DFS were significantly longer in patients treated with neoadjuvant therapy. 
Interestingly, as there were no significant differences in patients treated in 2000-2009, 
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patients treated in 2010-2015 showed 9 months longer DSS and 12 months longer DFS 
in patients treated with neoadjuvant therapy. Improvement could be due to more 
effective systemic treatments. In the 2010s new regimens such as folfirinox and nab-
paclitaxel have been used at our institution. In addition, our data showed that nowadays 
gemcitabine is more often combined with other agents, such as cisplatin. The 
improvement is emphasized by median DFS increasing significantly from the 2000s to 
2010s, from 15 to 25 months. Although survival has not improved for patients 
undergoing upfront surgery, these results are encouraging for borderline resectable 
PDAC patients treated with neoadjuvant therapy. Similar findings have been reported 
before by Cloyd et al. [19], who divided 622 patients treated in 1990-2014 with 
neoadjuvant therapy and subsequent surgery into four successive time periods. Median 
overall survival improved drastically from 24 to 43 months. In addition, there was a 
randomized controlled trial in Korea aiming at 110 patients receiving neoadjuvant 
therapy. The aim was to compare survival to patients undergoing upfront surgery. 
However, the trial was ended at interim analysis, since the survival differences were so 
drastic in favour of neoadjuvant therapy [20].  
Locally advanced unresectable pancreatic cancer has been treated with 
systemic chemotherapy with or without radiation for decades [21,22]. Overall survival 
has been reported to be 6-11 months [21,22]. Compared to our results, downstaging the 
disease to resectable with chemo(radio)therapy results in significantly longer survival 
(median 35 vs. 6-11 months). More aggressive surgery has been advocated as well, but 
it has been reported that extended pancreatectomy does not guarantee better survival for 
more advanced disease; mortality and morbidity after surgery increase but survival is 
not affected [23].  
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Tumour grade is a known prognostic factor in pancreatic cancer.  It has 
even been postulated to have a stronger impact on survival than tumour size and lymph 
node positivity [24]. However, there are no studies on the prognostic impact of tumour 
grade in patients treated with neoadjuvant therapy. Our results suggest that neoadjuvant 
therapy may be effective especially in patients with poorly differentiated PDAC. This is 
supported by both longer DSS and DFS in patients with grade 3 tumour treated with 
neoadjuvant therapy than in patients undergoing upfront surgery; both median DSS and 
DFS showed a threefold increase in survival. The multivariate analyses also showed that 
neoadjuvant therapy had a protective effect on both DSS and DFS in patients with grade 
3 tumours. Hence, it could be argued that oncologic treatment is more effective in 
aggressive disease. This is supported by the fact that similar survival differences were 
not recognised in patients with grade 1 or 2 tumours. However, tumour grade is not 
usually known prior to treatment due to scarce biopsy material. To achieve patient-
specific treatment, more advanced diagnostic techniques are awaited.  
Crippa et al. pondered the effectiveness of pancreatic surgery for grade 3 
tumour patients [25]. Grade 3 tumour patients had clearly worse DSS (20 vs. 77 
months) and DFS (9 vs. 63 months) when compared to grade 1 tumour patients. Also, 
the study showed that grade 3 tumour patients were most likely to benefit from adjuvant 
therapy (HR 2.11) [25]. The study recommended neoadjuvant therapy for grade 3 
tumour patients. Our results support the recommendation.  
Prognostic factors are universal for resectable pancreatic cancer patients 
and might not be adaptable to patients treated with neoadjuvant therapy. Table 4 shows 
that tumour grade, stage and resection margins are prognostic for patients undergoing 
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upfront surgery. However, they do not seem to apply to patients treated with 
neoadjuvant therapy in the same way.  
Stage is widely recognised as a prognostic factor in pancreatic cancer. 
Lymph node negativity and especially low LNR have been associated with better 
survival in resectable pancreatic cancer [26]. Here, we divided patients into lymph node 
negative (0-IIA) and positive groups (IIB-III) according to stage. Here, too, neoadjuvant 
therapy seems to be effective in aggressive and advanced disease. Median DSS was 14 
and DFS 11 months longer in stage IIB-III patients treated with neoadjuvant therapy 
than upfront surgery. There were no survival differences between lower stage patients.  
There is most likely downstaging due to neoadjuvant therapy, which is 
supported by fewer nodal metastases, smaller tumour size and thus, lower stage. 
Patients treated with neoadjuvant therapy had a more favourable stage distribution than 
patients undergoing upfront surgery. This might, in fact, affect survival and multivariate 
analyses. De Geus et al. analysed neoadjuvant therapy and subsequent surgery versus 
upfront surgery and adjuvant therapy and found that neoadjuvant therapy showed a 
higher median survival in stage III patients (23 vs. 17 months) but not in early stage 
patients [13]. However, a larger study of 8026 patients comparing neoadjuvant therapy 
and upfront surgery found that neoadjuvant therapy has a significant survival benefit 
(26 vs. 21 months) over upfront surgery in early stage pancreatic cancer [12]. These 
results are inconclusive and demonstrate the inability to compare different studies due 
to heterogeneity and different criteria for study inclusion and resectability.  
R1 resection is seen as a strong negative prognostic marker in pancreatic 
cancer and R1 resections are more commonly seen in borderline resectable pancreatic 
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cancer due to contact with nearby blood vessels [27]. In our study, the proportion of R0 
and R1 resections did not differ between studied groups. Survival comparison according 
to R0/R1 status revealed no differences in DSS, however, DFS was longer in both R0 
and R1 resected patients who had been treated with neoadjuvant therapy indicating that 
neoadjuvant therapy delays disease progression. 
Grouping patients according to preoperative and postoperative treatment 
showed that clearly the longest survival was achieved with perioperative treatment and 
shortest with surgical treatment only. It is, however, unclear whether there is a 
meaningful difference in survival time between neoadjuvant therapy followed by 
surgery and surgery followed by postoperative adjuvant therapy. This, quite possibly, is 
dependent on tumour biology.   
We acknowledge the limitations to this study; the study is retrospective, 
which could indicate selection bias. Also, the neoadjuvant therapy protocol has changed 
during the past 15 years with the addition of changing imaging and evaluation of 
resectability protocols. The multivariate results should be considered with caution due 
to limited number of patients with grade 3 tumours. However, these factors have been 
minimised by the fact that the propensity matched controls have been treated at the 
same time. The study does not consider a comparative non-resectable group, nor does it 
identify the patients with progressive disease during neoadjuvant therapy or those who 
could not finish their treatment due to other reasons. In Finland, preoperative diagnosis 
is mostly based on brush cytology, from which PDAC is impossible to diagnose. 
In conclusion, this study emphasizes the fact that more aggressive disease 
and later stage PDAC patients benefit from neoadjuvant therapy; patients with grade 3 
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tumours presented with three times longer DSS and DFS when treated with neoadjuvant 
therapy. Survival has improved for borderline resectable PDAC patients treated with 
neoadjuvant therapy over the past 15 years. Whether to administer neoadjuvant therapy 
to early stage patients is still controversial. Due to possible selection bias and a vast 
variety of heterogeneous studies, further prospective and randomised controlled trials 
are much needed. 
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Figure legends: 
Figure 1A. DSS in operated PDAC patients (2010-2015) according to preoperative 
treatment. Median survival for neoadjuvant therapy was 35 (95% CI 25-44) months and 
for upfront surgery 26 (95% CI 20-31) months, p=0.008.   
 
Figure 1B. DFS in operated PDAC patients (2010-2015) according to preoperative 
treatment. Median survival for neoadjuvant therapy was 25 (95% CI 13-36) months and 
for upfront surgery 13 (95% CI 6-21) months, p=0.001.   
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Figure 2A. DSS in patients with grade 3 tumour according to preoperative treatment. 
Patients: n(NEO)=14, n(US)=26. Median survival for neoadjuvant therapy 30 (95% CI 
17-42) months and for upfront surgery 11 (95% CI 8-15) months, p=0.004. 
NEO=Neoadjuvant therapy, US=Upfront surgery. 
 
 
Figure 2B. DFS in patients with grade 3 tumour according to preoperative treatment. 
Patients: n(NEO)=14, n(US)=26. Median survival for neoadjuvant therapy was 21 (95% 
CI 11-31) months and for upfront surgery 7 (95% CI 5-8) months, p=0.001. 
NEO=Neoadjuvant therapy, US=Upfront surgery. 
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Figure 3A. DSS in operated stage IIB-III pancreatic cancer patients according to 
preoperative treatment. Patients: n(NEO)=35, n(US)=107. Median survival for 
neoadjuvant therapy was 34 (95% CI 29-40) months and for upfront surgery 20 (95% 
CI 14-26) months, p=0.006. NEO=Neoadjuvant therapy, US=Upfront surgery.  
 
Figure 3B. DFS in operated stage IIB-III pancreatic cancer patients according to 
preoperative treatment. Patients: n(NEO)=35, n(US)=107. Median survival for 
neoadjuvant therapy was 21 (95% CI 12-29) months and for upfront surgery 10 (95% 
CI 7-13) months, p=0.001. NEO=Neoadjuvant therapy, US=Upfront surgery. 
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Table 1. Patient characteristics of PDAC patients operated in 2000-2015 according to 
preoperative treatment.  
 NEO (n=75) US (n=150) p-value 
Age at operation, median (range) 65 (40-83) 66 (45-82) NS 
≥65 years 39 (50%) 79 (53%) NS 
Gender, female 42 (56%) 83 (55%) NS 
pTN* (AJCC 7th edition)    
T0 3 (4%) 0 0.001 
T1 9 (12%) 5 (3%)  
T2 18 (25%) 30 (20%)  
T3 42 (58%) 115 (77%)  
T4 1 (1%) 0  
N0 38 (51%) 42 (28%) 0.001 
N1 36 (49%) 108 (72%)  
LNR*    
<20 % 66 (89%) 109 (74%) 0.009 
≥20 % 8 (11%) 39 (26%)  
Stage* (AJCC 7th edition)    
0 2 (3%) 0 0.000 
IA 5 (7%) 3 (2%)  
IB 10 (14%) 16 (11%)  
IIA 20 (27%) 23 (15%)  
IIB 34 (47%) 107 (71%)  
III 1 (1%) 0  
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IV** 1 (1%) 1 (1%)  
pTumor size (mm), median (IQR) 25 (20-30) 30 (25-40) 0.000 
Grade*    
1 11 (15%) 27 (18%) NS 
2 48 (66%) 97 (65%)  
3 14 (19%) 26 (17%)  
R0 resection* 58 (82%) 106 (75%) NS 
Vascular resection 34 (45%) 49 (33%) NS 
Perineural invasion* 47 (63%) 120 (81%) 0.005 
Perivascular invasion* 16 (21%) 58 (39%) 0.010 
Imaging (median in mm, range)    
Tumour size pre-therapy 31 (10-89)   
Tumour size post-therapy 23 (0-47)   
Size difference 9 (0-42)   
Missing/inadequate imaging 9 (12%)   
Preoperative laboratory results***    
CA 19-9 (ln(kU/l)), median (IQR) 4.4 (2.6-5.9) 4.8 (3.4-6.5) NS 
CEA (µg/l), median (IQR) 2.7 (1.7-3.9) 2.9 (1.8-5.0) NS 
NEO=Neoadjuvant therapy, US=Upfront surgery, AJCC=American Joint Committee on 
Cancer, LNR=lymph node ratio, IQR=interquartile range, NS=non-significant. 
*Missing data: two patients lacked adequate TNM classification and stage, three 
patients’ lymph node metastases were inconclusive. Information on perineural and 
perivascular invasion was missing in one patient. Resection margin status was missing 
in seven patients. No grade available in two patients due to complete response. 
**Preoperatively treated patient had an adrenal metastasis, and patient undergoing 
upfront surgery had a para-aortal lymph node metastasis. Metastases were not 
confirmed before surgery. These patients were excluded from survival analyses. 
***Mann-Whitney U-test. Natural logarithm was taken from CA19-9 value. 
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All 2x2 tests were done by using the Fisher’s exact test. Linear by linear association 
was used for tables with more than two rows. Missing data were excluded. 
 
Table 2. DSS and DFS in operated PDAC patients according to preoperative treatment.  
NEO=neoadjuvant therapy, US=upfront surgery, DSS=disease-specific survival, 
DFS=disease-free survival, NS=non-significant. Survival was estimated with Kaplan-
Meier and compared with the Breslow test. 
 
 
Table 3. DSS and DFS survival in operated PDAC patients according to different 
prognostic parameters and preoperative treatment.  
 NEO (95% CI) 
months 
US (95% CI)  
months 
p-value 
Patients treated in 2000-2015 (n=223)    
DSS 34 (29-39) 26 (20-32) 0.016 
DFS 22 (17-27) 13 (9-17) 0.001 
Patients treated in 2000-2009 (n=91)    
DSS 30 (22-38) 27 (17-37) NS 
DFS 15 (10-19) 12 (10-15) NS 
Patients treated in 2010-2015 (n=132)    
DSS 35 (25-44) 26 (20-31) 0.008 
DFS 25 (13-36) 13 (6-21) 0.001 
 NEO (95% CI) 
months 
p-value NEO vs. US 
 p-value 
US (95% CI) 
months 
p-value 
DSS       
Tumour grade 1 36 (34-38) NS NS 43 (32-54) 0.000 
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NEO=neoadjuvant therapy, US=upfront surgery, DSS=disease-specific survival, 
DFS=disease-free survival, NS=non-significant. Survival times were estimated with 
Kaplan-Meier and compared with the Breslow test. Stage according to AJCC 7th edition 
guidelines. 
 
 
 
 
Tumour grade 2 31 (27-34)  NS 27 (20-35)  
Tumour grade 3 30 (17-42)  0.004 11 (8-15)  
DFS       
Tumour grade 1 23 (15-31) NS NS 18 (12-25) 0.000 
Tumour grade 2 18 (12-25)  NS 13 (8-18)  
Tumour grade 3 21 (11-31)  0.001 7 (5-8)  
DSS       
Stage 0-IIA 31 (25-37) NS NS 45 (33-56) 0.004 
Stage IIB-III 34 (29-40)  0.006 20 (14-26)  
DFS       
Stage 0-IIA 19 (13-26) NS NS 24 (7-41) 0.003 
Stage IIB-III 21 (12-29)  0.001 10 (7-13)  
DSS       
R0 margin 36 (34-38) NS NS 29 (21-37) NS 
R1 margin 31 (14-47)  NS 17 (12-21)  
DFS       
R0 margin 23 (17-29) NS 0.028 16 (11-21) 0.001 
R1 margin 17 (11-22)  0.024 7 (2-11)  
